Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation.

ABSTRACT:

Abstract

Cutaneous sclerosis, a highly morbid subtype of chronic graft-versus-host disease (GVHD), demonstrates limited treatment response under current National Institutes of Health (NIH) response measures. We explored novel sclerosis-specific response measures using Chronic GVHD Consortium data. A training cohort included patients with cutaneous sclerosis from a randomized trial of imatinib vs rituximab and a consortium observational study. The validation cohort was a different consortium observational study. Clinician-reported measures (baseline and baseline to 6-month change) were examined for association with 6-month clinician-reported response. Patient-reported measures (baseline and baseline to 6-month change) were studied for association with 6-month patient-reported respon

SUBMITTER: Pidala JA 

PROVIDER: S-EPMC11402177 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature